Terms: = Kidney tumors AND PDCD1, CD279, PD-1, PD1, SLEB2, hPD-1, hPD-l, hSLE1 AND Clinical Outcome
24 results:
1. Activation of endogenous glucocorticoids by HSD11B1 inhibits the antitumor immune response in renal cancer.
Poinot H; Dupuychaffray E; Arnoux G; Alvarez M; Tachet J; Ezzar O; Moore J; Bejuy O; Olesti E; Visconti G; González-Ruiz V; Rudaz S; Tille JC; Voegel CD; Nowak-Sliwinska P; Bourquin C; Pommier A
Oncoimmunology; 2024; 13(1):2286820. PubMed ID: 38170044
[TBL] [Abstract] [Full Text] [Related]
2. APOBEC3C is a novel target for the immune treatment of lower-grade gliomas.
Zhao S; Li Y; Xu J; Shen L
Neurol Res; 2024 Mar; 46(3):227-242. PubMed ID: 38007705
[TBL] [Abstract] [Full Text] [Related]
3. Upregulation of CENPM is associated with poor clinical outcome and suppression of immune profile in clear cell renal cell carcinoma.
Zhang ZC; Liu YF; Xi P; Nie YC; Sun T; Gong BB
Hereditas; 2023 Jan; 160(1):1. PubMed ID: 36635779
[TBL] [Abstract] [Full Text] [Related]
4. Wilms tumor reveals DNA repair gene hyperexpression is linked to lack of tumor immune infiltration.
Higgs EF; Bao R; Hatogai K; Gajewski TF
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35705315
[TBL] [Abstract] [Full Text] [Related]
5. Role of 18F-FDG PET/CT in the assessment of therapy response and clinical outcome in metastatic renal cell carcinoma treated with tyrosine kinase inhibitors or immunotherapy.
Tatar G; Alçin G; Şengül Samanci N; Erol Fenercioglu Ö; Beyhan E; Çermik TF
Nucl Med Commun; 2022 Jun; 43(6):701-709. PubMed ID: 35362692
[TBL] [Abstract] [Full Text] [Related]
6. A genomic instability-derived risk index predicts clinical outcome and immunotherapy response for clear cell renal cell carcinoma.
Wu S; Li X
Bioengineered; 2021 Dec; 12(1):1642-1662. PubMed ID: 33955826
[TBL] [Abstract] [Full Text] [Related]
7. Landscape of immune cell infiltration in clear cell renal cell carcinoma to aid immunotherapy.
Bai D; Feng H; Yang J; Yin A; Qian A; Sugiyama H
Cancer Sci; 2021 Jun; 112(6):2126-2139. PubMed ID: 33735492
[TBL] [Abstract] [Full Text] [Related]
8. Intratumoral CXCL13
Dai S; Zeng H; Liu Z; Jin K; Jiang W; Wang Z; Lin Z; Xiong Y; Wang J; Chang Y; Bai Q; Xia Y; Liu L; Zhu Y; Xu L; Qu Y; Guo J; Xu J
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33589528
[TBL] [Abstract] [Full Text] [Related]
9. CD8+CD103+ tissue-resident memory T cells convey reduced protective immunity in cutaneous squamous cell carcinoma.
Lai C; Coltart G; Shapanis A; Healy C; Alabdulkareem A; Selvendran S; Theaker J; Sommerlad M; Rose-Zerilli M; Al-Shamkhani A; Healy E
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33479027
[TBL] [Abstract] [Full Text] [Related]
10. Anti-pd-1/L1-associated immune-related adverse events as harbinger of favorable clinical outcome: systematic review and meta-analysis.
Park R; Lopes L; Saeed A
Clin Transl Oncol; 2021 Jan; 23(1):100-109. PubMed ID: 32495269
[TBL] [Abstract] [Full Text] [Related]
11. PD-L1 expression is an unfavourable prognostic indicator in Asian renal cell carcinomas.
Yeong J; Zhao Z; Lim JCT; Li H; Thike AA; Koh VCY; Teh BT; Kanesvaran R; Toh CK; Tan PH; Khor LY
J Clin Pathol; 2020 Aug; 73(8):463-469. PubMed ID: 31980560
[TBL] [Abstract] [Full Text] [Related]
12. PD-L1 expression and infiltration by CD4
Lee HJ; Shin DH; Lee YJ; Lee SJ; Hwang CS; Kim A; Park WY; Lee JH; Choi KU; Kim JY; Lee CH; Sol MY; Park SW
Histopathology; 2020 Apr; 76(5):714-721. PubMed ID: 31841221
[TBL] [Abstract] [Full Text] [Related]
13. Development of a prognostic composite cytokine signature based on the correlation with nivolumab clearance: translational PK/PD analysis in patients with renal cell carcinoma.
Wang R; Zheng J; Shao X; Ishii Y; Roy A; Bello A; Lee R; Zhang J; Wind-Rotolo M; Feng Y
J Immunother Cancer; 2019 Dec; 7(1):348. PubMed ID: 31829287
[TBL] [Abstract] [Full Text] [Related]
14. Toxicity associated with pd-1 blockade after allogeneic haematopoietic cell transplantation.
Ortega Sanchez G; Stenner F; Dirnhofer S; Passweg J; Gerull S; Halter JP; Zippelius A; Läubli H
Swiss Med Wkly; 2019 Nov; 149():w20150. PubMed ID: 31707719
[TBL] [Abstract] [Full Text] [Related]
15. Nivolumab-induced Adrenal Insufficiency in Patients With Renal Cell Carcinoma.
Suzuki K; Terakawa T; Furukawa J; Harada K; Hinata N; Nakano Y; Fujisawa M
J Immunother; 2020 Jan; 43(1):38-42. PubMed ID: 31567704
[TBL] [Abstract] [Full Text] [Related]
16. A prospective cohort study on the pharmacokinetics of nivolumab in metastatic non-small cell lung cancer, melanoma, and renal cell cancer patients.
Hurkmans DP; Basak EA; van Dijk T; Mercieca D; Schreurs MWJ; Wijkhuijs AJM; Bins S; Hoop EO; Debets R; Joerger M; Odink A; van der Veldt AAM; van der Leest CH; Aerts JGJV; Mathijssen RHJ; Koolen SLW
J Immunother Cancer; 2019 Jul; 7(1):192. PubMed ID: 31324223
[TBL] [Abstract] [Full Text] [Related]
17. Tumor Cells Hijack Macrophage-Produced Complement C1q to Promote Tumor Growth.
Roumenina LT; Daugan MV; Noé R; Petitprez F; Vano YA; Sanchez-Salas R; Becht E; Meilleroux J; Clec'h BL; Giraldo NA; Merle NS; Sun CM; Verkarre V; Validire P; Selves J; Lacroix L; Delfour O; Vandenberghe I; Thuilliez C; Keddani S; Sakhi IB; Barret E; Ferré P; Corvaïa N; Passioukov A; Chetaille E; Botto M; de Reynies A; Oudard SM; Mejean A; Cathelineau X; Sautès-Fridman C; Fridman WH
Cancer Immunol Res; 2019 Jul; 7(7):1091-1105. PubMed ID: 31164356
[TBL] [Abstract] [Full Text] [Related]
18. A Genetic Polymorphism in
Liu X; Swen JJ; Diekstra MHM; Boven E; Castellano D; Gelderblom H; Mathijssen RHJ; Vermeulen SH; Oosterwijk E; Junker K; Roessler M; Alexiusdottir K; Sverrisdottir A; Radu MT; Ambert V; Eisen T; Warren A; Rodríguez-Antona C; García-Donas J; Böhringer S; Koudijs KKM; Kiemeney LALM; Rini BI; Guchelaar HJ
Clin Cancer Res; 2018 May; 24(10):2350-2356. PubMed ID: 29490989
[No Abstract] [Full Text] [Related]
19. Tim-3 Expression on Tumor-Infiltrating pd-1
Granier C; Dariane C; Combe P; Verkarre V; Urien S; Badoual C; Roussel H; Mandavit M; Ravel P; Sibony M; Biard L; Radulescu C; Vinatier E; Benhamouda N; Peyromaure M; Oudard S; Méjean A; Timsit MO; Gey A; Tartour E
Cancer Res; 2017 Mar; 77(5):1075-1082. PubMed ID: 27872087
[TBL] [Abstract] [Full Text] [Related]
20. Independent association of PD-L1 expression with noninactivated VHL clear cell renal cell carcinoma-A finding with therapeutic potential.
Kammerer-Jacquet SF; Crouzet L; Brunot A; Dagher J; Pladys A; Edeline J; Laguerre B; Peyronnet B; Mathieu R; Verhoest G; Patard JJ; Lespagnol A; Mosser J; Denis M; Messai Y; Gad-Lapiteau S; Chouaib S; Belaud-Rotureau MA; Bensalah K; Rioux-Leclercq N
Int J Cancer; 2017 Jan; 140(1):142-148. PubMed ID: 27623354
[TBL] [Abstract] [Full Text] [Related]
[Next]
